Syngene International Limited has announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb until 2035. This expanded agreement broadens the scope of integrated services across the entire drug development lifecycle, including discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, and data and information technology services.

The collaboration, which began in 1998, has seen the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene's first dedicated R&D Center, commissioned in 2009. The BBRC currently houses around 700 Syngene scientists and supports Bristol Myers Squibb's global research organization, contributing to discovery, preclinical development, and patent filings across various therapeutic areas. This extension aims to enable joint planning for future capabilities and infrastructure development, reinforcing Syngene's position as a strategic partner.

Peter Bains, Managing Director and CEO of Syngene International Ltd., highlighted the partnership's foundation in scientific excellence and a shared commitment to advancing innovative therapies. Payal Sheth, Senior Vice President at Bristol Myers Squibb, emphasized the value of the partnership in accelerating the delivery of transformative medicines to patients.